Study guide
1.2 Methadone Pharmacology, OTP Federal Regulations, QTc Prolongation & CYP450 Interactions
Certified Addictions Registered Nurse - Advanced Practice CARN-AP
Track your progress as you read
Finished sections get a check mark.
1 Introduction: The CARN-AP Examination & Foundations of Advanced Addictions Practice
About the CARN-AP Examination: Blueprint, Scoring & Eligibility The Neurobiology of Addiction: Binge, Withdrawal & Preoccupation Screening, SBIRT & the ASAM Criteria Levels of Care
2 Chapter 1: Opioid Use Disorder: Assessment, Overdose Response & Methadone Maintenance
1.1 OUD Assessment, DSM-5-TR Diagnostic Criteria, and Clinical Opiate Withdrawal Scale (COWS) 1.2 Methadone Pharmacology, OTP Federal Regulations, QTc Prolongation & CYP450 Interactions 1.3 Opioid Overdose Assessment, Harm Reduction, Naloxone Formulations & Nalmefene
3 Chapter 2: Buprenorphine Protocols, Long-Acting Injectables & Naltrexone
2.1 Buprenorphine Pharmacology, Standard Office/Home Induction & Precipitated Withdrawal Management 2.2 Low-Dose Micro-Induction (Bernese Method) & Fentanyl Transition Strategies 2.3 Long-Acting Injectable Buprenorphine (Sublocade, Brixadi) & Extended-Release Naltrexone (Vivitrol)
4 Chapter 3: Alcohol Use Disorder: Neurobiology, Assessment & Acute Withdrawal
3.1 AUD Neurobiology, Epidemiology, Screening Instruments (AUDIT, AUDIT-C, CAGE) & Laboratory Biomarkers 3.2 Alcohol Withdrawal Syndrome, CIWA-Ar Protocol, Symptom-Triggered Benzodiazepine Regimens & Delirium Tremens 3.3 Wernicke-Korsakoff Syndrome, High-Dose Parenteral Thiamine Protocols & Acute Medical Complications
5 Chapter 4: Medications for Alcohol Use Disorder (MAUD)
4.1 Oral and Injectable Naltrexone for AUD: Mechanism, Prescribing Protocols & Clinical Efficacy 4.2 Acamprosate Calcium: NMDA Modulation, Renal Dosing Parameters & Abstinence Maintenance 4.3 Disulfiram and Second-Line / Off-Label MAUDs: Topiramate, Gabapentin & Baclofen
6 Chapter 5: Stimulant, Sedative-Hypnotic & Synthetic Substance Use Disorders
5.1 Stimulant Use Disorder (Cocaine & Methamphetamine): Neurotoxicity, Medical Emergencies & Evidence-Based Interventions 5.2 Sedative, Hypnotic, and Anxiolytic Disorders: Dependence Physiology, Risks & Outpatient Tapering Protocols 5.3 Emerging Synthetic Drugs: Fentanyl Analogues, Synthetic Cathinones, Cannabinoids & Xylazine-Associated Necrotic Wounds
7 Chapter 6: Tobacco and Cannabis Use Disorders: Evidence-Based Pharmacotherapy & Interventions
6.1 Tobacco Use Disorder & Nicotine Dependence: Dual NRT, Varenicline & Bupropion Prescribing Protocols 6.2 Cannabis Use Disorder, Synthetic Cannabinoids & Cannabinoid Hyperemesis Syndrome 6.3 Behavioral Therapies in Substance Use: Motivational Interviewing, CBT & Contingency Management
8 Chapter 7: Psychiatric Differential Diagnosis & Medical Mimics in Addictions
7.1 Diagnostic Formulation: Primary vs. Substance-Induced Psychiatric Disorders & The 30-Day Rule 7.2 Endocrine, Neurological, and Metabolic Mimics of Substance Intoxication and Withdrawal 7.3 Decisional Capacity, Competency, and Involuntary Commitment in Acute Addiction Practice
9 Chapter 8: Co-Occurring Psychiatric Disorders: Integrated Treatment Planning
8.1 Integrated Dual Diagnosis Treatment (IDDT) Framework & High-Prevalence Mood / Anxiety Co-Occurring Disorders 8.2 Complex Severe Mental Illness: Psychotic Disorders, Bipolar Disorder & Borderline Personality in Addictions 8.3 Trauma-Informed Care, PTSD, and Addictions: Evidence-Based Integrated Psychotherapy
10 Chapter 9: Pain Management in Substance Use Disorders & CDC 2022 Guidelines
9.1 CDC 2022 Clinical Practice Guideline for Prescribing Opioids for Chronic Pain: Individualized Assessment vs. Hard Caps 9.2 Multimodal Non-Opioid Pharmacotherapy, Interventional Modalities & Non-Pharmacological Strategies 9.3 Acute Pain Management in Patients on Maintenance MOUD (Methadone, Buprenorphine, Naltrexone)
11 Chapter 10: Perinatal Substance Use, Neonatal Abstinence & Infectious Complications
10.1 Perinatal Substance Use Disorder: ACOG/ASAM Guidelines, MOTHER Trial & Maintenance MOUD 10.2 Neonatal Abstinence Syndrome (NAS/NOWS): Finnegan Scoring vs. Eat, Sleep, Console (ESC) & Breastfeeding 10.3 Infectious Complications in People Who Inject Drugs: Viral Hepatitis, HIV, Endocarditis & PrEP/PEP
12 Chapter 11: Federal Regulations, Confidentiality & Controlled Substance Prescribing
11.1 Controlled Substances Act, DEA Registration, Schedule Classifications & MAT Act of 2023 11.2 Confidentiality of Substance Use Disorder Patient Records: 42 CFR Part 2 (2024 Final Rule) & HIPAA Harmonization 11.3 Prescription Drug Monitoring Programs (PDMP) & Urine Drug Testing (UDT) Interpretation
13 Chapter 12: APRN Scope of Practice, Ethical Foundations, Harm Reduction & Research Literacy
12.1 APRN Scope of Practice, Prescriptive Authority & Collaborative Practice Regulations 12.2 Ethical Dilemmas in Addictions Nursing: Stigma, Autonomy, Justice, and Maternal/Fetal Rights 12.3 Harm Reduction Philosophy, Syringe Service Programs, Drug Checking & Overdose Prevention 12.4 Landmark Clinical Trials & Research Literacy in Addictions Medicine
14 Chapter 13: Stimulant Use Disorder in Depth — Methamphetamine, Withdrawal, Treatment & Harm Reduction
13.1 Methamphetamine Use Disorder: Pharmacology, Medical & Psychiatric Sequelae 13.2 Stimulant Withdrawal, Craving & Contingency Management 13.3 Pharmacotherapy Research for Stimulant Use Disorder 13.4 Stimulant Harm Reduction, Overamping & Patient Education
15 Chapter 14: Medical Consequences of Alcohol Use — Liver, Heart, Cancer & Nutrition
14.1 Alcohol-Associated Liver Disease: Staging, Scoring & Management 14.2 Cardiovascular, Oncologic & Nutritional Consequences of Alcohol
16 Chapter 15: Brief Intervention, Drinking Goals & Recovery Support in Alcohol Use Disorder
15.1 Brief Intervention, Drinking Goals & Shared Decision Making in AUD 15.2 Relapse Prevention, Mutual-Help Programs & Recovery Support
17 Chapter 16: Tobacco Use Disorder in Depth — Neurobiology, Assessment & Special Populations
16.1 Nicotine Neurobiology, Epidemiology & the Tobacco Product Landscape 16.2 Tobacco Assessment & Behavioral Treatment: 5 A's, Quitlines & Incentives 16.3 Tobacco Treatment in Special Populations & Co-Occurring Disorders
18 Chapter 17: Cannabis Use Disorder in Depth — Products, Treatment & Policy
17.1 Cannabinoid Pharmacology, Potency & the Modern Product Landscape 17.2 Cannabis Use Disorder: Epidemiology, Assessment & Treatment Evidence 17.3 Medical Cannabis, Legalization Policy, Adolescent Risk & Patient Education
19 Chapter 18: Other Use Disorders — Inhalants, Hallucinogens, Process Addictions & Prescription/OTC Misuse
18.1 Inhalant Use Disorder: Volatile Solvents, Nitrous Oxide & Alkyl Nitrites 18.2 Hallucinogens & Dissociatives: Classic Psychedelics, PCP, Ketamine & HPPD 18.3 Process (Behavioral) Addictions: Gambling Disorder, Gaming & Compulsive Behaviors 18.4 Prescription & Over-the-Counter Substance Misuse: Opioids, Stimulants, Kratom & DXM
20 Chapter 19: Educating Patients, Families & the Public (CARN-AP Activity Area III)
19.1 Designing Health Teaching: Literacy, Readiness, Culture & Teach-Back 19.2 Medication Education, Informed Consent & Informed Refusal 19.3 Family & Support-System Education: CRAFT, Al-Anon & Overdose Prevention Teaching 19.4 Public, Professional & Anticipatory Guidance: Prevention and Advocacy Teaching
21 Chapter 20: Consultation, Collaboration & Care Coordination (CARN-AP Activity Area IV)
20.1 The APRN Consultation Process & Communicating Recommendations 20.2 Interprofessional Collaboration, Care Coordination & Transitions of Care 20.3 Community Resources, Systems Navigation & Collaborative Documentation
22 Chapter 21: Quality Improvement, Evidence & Leadership in Addictions Nursing (CARN-AP Activity Area V)
21.1 Outcome Measurement & Continuous Quality Improvement in Addictions Care 21.2 Policy Advocacy, Leadership & the Determinants of Addiction
1.2 Methadone Pharmacology, OTP Federal Regulations, QTc Prolongation & CYP450 Interactions
Key Takeaways Explain This Topic AI
Methadone is a racemic mixture: (R)-methadone provides full mu-opioid receptor agonism with no ceiling effect, while (S)-methadone acts as an NMDA receptor antagonist.
Methadone's elimination half-life (8-59 hours) far exceeds its 4-8 hour analgesia; steady-state requires 4-10 days, making Day 1 dosing (20-30 mg, max 40 mg) and conservative titration (5-10 mg q3-5d) vital to prevent fatal accumulation.
The SAMHSA 2024 Final Rule (42 CFR Part 8) modernized OTP regulations: expedited take-homes (up to 7 days in days 0-14, 14 days in days 15-30, 28 days from day 31+), eliminated the 1-year addiction history rule, and codified APRN dispensing authority.
Methadone blocks cardiac hERG potassium channels; QTc ≥500 ms represents a critical threshold requiring immediate dosage reduction, cardiology evaluation, or transition to buprenorphine.
Metabolism is mediated by CYP3A4, CYP2B6, and CYP2D6; potent inducers (rifampin, carbamazepine) trigger acute withdrawal, whereas potent inhibitors (fluconazole) cause fatal opioid toxicity.
Last updated: September 2026
Methadone Pharmacology, Federal OTP Regulations & Advanced Clinical Management
Methadone is a synthetic, long-acting opioid agonist utilized worldwide for the treatment of Opioid Use Disorder (OUD) and chronic pain. For the Advanced Practice Registered Nurse (CARN-AP), safe prescribing requires deep fluency in its unique stereospecific pharmacology , variable clearance kinetics, complex Cytochrome P450 interactions , electrophysiological QTc prolongation risks , and the regulatory governance established by 42 CFR Part 8 as overhauled by the SAMHSA 2024 Final Rule .
Stereospecific Pharmacology & Dual Receptor Mechanism
Methadone is administered clinically as a racemic mixture (50:50) of two enantiomers: (R)-methadone (levomethadone) and (S)-methadone (dextromethadone). Each enantiomer confers distinct pharmacodynamic properties: RACEMIC METHADONE HYDROCHLORIDE
- |
- +----------------------------+----------------------------+
- | |
- (R)-Methadone (Levorotatory) (S)-Methadone (Dextrorotatory)
- Full Mu-Opioid Receptor (MOR) Agonist - NMDA Receptor Antagonist (Non-competitive)
- 10 to 50x higher affinity than (S)-form - Low opioid receptor affinity
- No ceiling effect on efficacy - Counteracts central sensitization & tolerance
- Suppresses withdrawal & cravings - Attenuates opioid-induced hyperalgesia (OIH)
- Blocks illicit opioid euphoria (cross-tolerance) - Contributes significantly to hERG QTc blockade
- | |
- +----------------------------+----------------------------+
- |
- Dual Monoamine Reuptake Inhibition
- Inhibits Serotonin (5-HT) and Norepinephrine (NE) reuptake
- Neuropathic pain relief / Risk of Serotonin Syndrome with SSRIs/SNRIs/MAOIs
(R)-Methadone (Levorotatory):
High-affinity full mu-opioid receptor (MOR) agonist ( 10 − 50 × 10-50\times 10 − 50 × greater affinity than (S)-methadone).
High intrinsic efficacy with no therapeutic ceiling on analgesia or respiratory depression.
Sustained MOR occupancy relieves withdrawal symptoms, eliminates drug hunger/craving, and produces cross-tolerance that blocks the subjective "high" from illicit opioids.
(S)-Methadone (Dextrorotatory):
Negligible opioid receptor activity.
Potent, non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist .
Inhibits glutamate excitotoxicity, prevents or reverses opioid tolerance, and attenuates neuropathic pain and opioid-induced hyperalgesia (OIH).
Binds strongly to the cardiac hERG potassium channel, contributing disproportionately to cardiac repolarization delay.
Monoaminergic Activity:
Both enantiomers act as moderate inhibitors of presynaptic serotonin (5-HT) and norepinephrine (NE) reuptake .
Contributes to efficacy in treating chronic pain syndromes, but carries a clinical risk of Serotonin Syndrome when combined with serotonergic medications (e.g., SSRIs, SNRIs, TCAs, MAOIs, triptans, linezolid).
Pharmacokinetics, Bioavailability & The Steady-State Accumulation Hazard
Methadone's pharmacokinetic profile is marked by profound inter-individual variability, extensive tissue sequestration, and a profound dissociation between its duration of analgesia and its elimination half-life.
Absorption and Distribution
Oral Bioavailability: High, ranging from 70% to 90% , with rapid gastrointestinal absorption.
Peak Plasma Concentration ( T max T_{\max} T m a x ): Typically reached within 2 to 4 hours post-oral ingestion.
Volume of Distribution ( V d V_d V d ): Highly lipophilic, with a massive volume of distribution ranging from 3.0 to 5.0 L/kg .
Protein Binding: Highly bound (85% to 90%) to plasma proteins, predominantly alpha-1-acid glycoprotein (AAG) . Because AAG is an acute-phase reactant, conditions such as chronic infection, malignancy, trauma, or pregnancy can alter free unbound methadone concentrations.
Biphasic Elimination and The Accumulation Hazard
Methadone undergoes biphasic elimination:
An initial distribution phase (alpha phase) with a half-life of 2 to 4 hours.
A terminal elimination phase (beta phase) characterized by a wide, erratic half-life ranging from 8 to 59 hours (mean ~24 to 36 hours) . THE FATAL STEADY-STATE ACCUMULATION TRAP
- Analgesic / Subjective Window: 4 - 8 Hours
- Elimination Half-Life: 24 - 36 Hours (up to 59h)
- Time to Steady-State (3-5 t1/2): 4 - 10 Days
Day 1: Dose administered (e.g., 30 mg). Tissues unsaturated. Patient feels partial relief.
Day 2-3: Dose raised too quickly (e.g., to 50-60 mg). Tissue reservoirs progressively fill.
Day 4-6: STEADY-STATE SURGE. Tissue depots saturate; free plasma levels spike.
FATAL NOCTURNAL OVERDOSE occurs during sleep due to cumulative drug burden.
The "Day 4 to 6" Clinical Danger: Because the subjective or analgesic effect of methadone lasts only 4 to 8 hours, patients feel the medication "wearing off" in the afternoon or evening during the first few days of treatment. If an inexperienced clinician escalates the dose on Day 2 or Day 3, the drug accumulates in peripheral fat and liver depots. When steady-state is finally reached at 4 to 10 days (3.3 to 5 elimination half-lives) , accumulated plasma levels surge, resulting in delayed, fatal nocturnal respiratory arrest.
Federal Regulations: 42 CFR Part 8 & SAMHSA 2024 Final Rule
Methadone maintenance for Opioid Use Disorder can only be dispensed through federally certified Opioid Treatment Programs (OTPs) governed by Title 42 of the Code of Federal Regulations, Part 8 (42 CFR Part 8) , overseen by the Substance Abuse and Mental Health Services Administration (SAMHSA) and the Drug Enforcement Administration (DEA).
In February 2024, SAMHSA published a landmark Final Rule (effective April 2024, mandatory compliance October 2024) making permanent many COVID-19 flexibilities and fundamentally modernizing OTP clinical practice.
Key Revisions in the SAMHSA 2024 Final Rule +---------------------------------------------------------------------------------------------------------+
- | SAMHSA 2024 FINAL RULE (42 CFR PART 8) OVERVIEW |
- +-----------------------------------+---------------------------------------------------------------------+
- | Regulatory Domain | 2024 Modernized Federal Standards |
- +-----------------------------------+---------------------------------------------------------------------+
- | 1. Modernized Take-Home Schedule | - Days 0-14: Up to 7 calendar days of unsupervised take-homes |
- | | - Days 15-30: Up to 14 calendar days of unsupervised take-homes |
- | | - Days 31+: Up to 28 calendar days of unsupervised take-homes |
- | | (Decisions based on clinician assessment of stability, not time) |
- +-----------------------------------+---------------------------------------------------------------------+
- | 2. Elimination of 1-Year History | The historical requirement of a mandatory 1-year documented continuous|
- | | addiction history prior to OTP admission is completely eliminated. |
- +-----------------------------------+---------------------------------------------------------------------+
- | 3. Expanded APRN / PA Scope | Full federal authorization for APRNs and PAs to order, initiate, |
- | | and dispense methadone in OTPs within their state scope of practice.|
- +-----------------------------------+---------------------------------------------------------------------+
- | 4. Telehealth Initiation | Audio-visual telehealth allowed for methadone initiation if an |
- | | in-person evaluation is performed by an OTP-associated clinician. |
- +-----------------------------------+---------------------------------------------------------------------+
- | 5. 72-Hour Emergency Exemption | Under DEA 21 CFR 1306.07(b), hospital/ED clinicians may administer |
- | | methadone for up to 72 hours for acute withdrawal while arranging |
- | | OTP enrollment. |
- +-----------------------------------+---------------------------------------------------------------------+
- Clinical Stability Factors for Take-Home Authorization
Under 42 CFR § 8.12, before authorizing take-home medication, the APRN must assess and document:
Absence of active substance-induced impairment or acute intoxication.
Regularity of clinic attendance.
Absence of serious behavioral problems at the clinic.
Absence of known recent criminal activity related to drug use.
Stability of the patient's home environment and social relationships.
Safe storage ability (e.g., lockbox in a secure location).
Rehabilitation benefit outweighing the potential risk of diversion.
Cardiac Electrophysiology, hERG Blockade & QTc Monitoring Protocols
Methadone causes concentration-dependent inhibition of the hERG (human Ether-à-go-go-Related Gene, KCNH2 ) cardiac potassium channels in ventricular myocytes. This channel conducts the rapid delayed rectifier potassium current ( I K r I_{Kr} I Kr ), which mediates phase 3 repolarization of the ventricular action potential.
Pathophysiology of Torsades de Pointes (TdP)
Blocking I K r I_{Kr} I Kr delays ventricular repolarization, causing prolongation of the corrected QT (QTc) interval .
Delayed repolarization allows reactivated L-type calcium currents, generating Early After-Depolarizations (EADs) .
When an EAD reaches threshold voltage during the relative refractory period (the "R-on-T phenomenon"), it triggers Torsades de Pointes (TdP) —a polymorphic ventricular tachycardia with a characteristic twisting QRS morphology that frequently degenerates into ventricular fibrillation and sudden cardiac death. hERG POTASSIUM CHANNEL BLOCKADE
- |
- Prolongation of Cardiac Repolarization
- |
- Corrected QT (QTc) > 500 ms
- |
- Early After-Depolarizations (EADs)
- |
- R-on-T Ventricular Premature Beat
- |
- TORSADES DE POINTES (Polymorphic VT) -> Sudden Death
- QTc Stratification & Management Thresholds
Clinicians calculate QTc using standard Bazett ( Q T c = Q T / R R QTc = QT / \sqrt{RR} QT c = QT / RR ) or Fridericia ( Q T c = Q T / R R 3 QTc = QT / \sqrt[3]{RR} QT c = QT / 3 RR ) formulas:
Normal QTc: < 430 <430 < 430 ms for males; < 450 <450 < 450 ms for females.
Borderline QTc: 450 450 450 to 499 499 499 ms.
Critical / High Risk QTc: ≥ 500 \ge 500 ≥ 500 ms (or a baseline increase > 60 >60 > 60 ms).
Clinical Action Algorithm for QTc Prolongation
QTc < 450 ms: Normal. Proceed with standard titration.
QTc 450 - 499 ms:
Assess and correct electrolytes: maintain potassium ( K + K^+ K + ) > 4.0 >4.0 > 4.0 mEq/L and magnesium ( M g 2 + Mg^{2+} M g 2 + ) > 2.0 >2.0 > 2.0 mg/dL.
Screen and discontinue concurrent QT-prolonging medications (e.g., citalopram, haloperidol, azithromycin).
Repeat 12-lead ECG in 2 to 4 weeks during maintenance titration.
QTc ≥ \ge ≥ 500 ms (Critical):
Mandatory clinical action: Reduce the methadone daily dose immediately by 20% to 30% .
Obtain urgent cardiology consultation.
Strongly consider transitioning the patient to buprenorphine , a partial mu-agonist that possesses minimal affinity for the hERG channel and does not prolong QTc at therapeutic dosages.
If the patient refuses transition or tapering, arrange telemetry or close serial ECG monitoring.
Indications for Baseline 12-Lead Electrocardiogram
Proposed or current daily methadone dose > 100 >100 > 100 mg/day .
Pre-existing cardiac disease, history of myocardial infarction, heart failure, or bradyarrhythmia.
History of unexplained syncope, pre-syncope, or seizures.
Family history of premature sudden unexplained death or long QT syndrome.
Concomitant use of any known QT-prolonging agent.
History of severe electrolyte derangements (e.g., severe vomiting, anorexia, bulimia, diuretic use).
Cytochrome P450 Metabolism & Drug-Drug Interactions
Methadone undergoes extensive phase I hepatic clearance, converted into the inactive metabolite EDDP (2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine) and subsequently EMDP .
Metabolism is mediated predominantly by CYP3A4 and CYP2B6 , with minor pathways via CYP2D6 , CYP1A2 , and CYP2C19 . CYP2B6 exhibits stereoselective clearance of the active (R)-enantiomer. METHADONE HEPATIC METABOLISM
- (R,S)-Methadone (Active)
- |
- +------------------------------+------------------------------+
- | | |
- CYP3A4 CYP2B6 CYP2D6
- (Major Phase I) (Stereoselective for (R)) (Minor Pathway)
- | | |
- +------------------------------+------------------------------+
- |
- EDDP (Inactive Metabolite)
- Drug Interactions: Inducers vs. Inhibitors
Interaction Type Offending Pharmacologic Agents Mechanism Clinical Consequence & APRN Action
Potent CYP Inducers Rifampin , Phenytoin , Carbamazepine , Phenobarbital , Efavirenz , Nevirapine, St. John's Wort Dramatically accelerates methadone clearance (reduces plasma AUC by 50-80% within 48-72 hours) Precipitated severe withdrawal. Requires aggressive methadone dose increases (often 50-100% or split dosing) or switching antimicrobial/anticonvulsant.
Potent CYP Inhibitors Fluconazole , Ketoconazole, Voriconazole, Ciprofloxacin , Fluvoxamine , Clarithromycin, Cimetidine, Paroxetine Inhibits CYP3A4, CYP2B6, or CYP1A2, blocking metabolic clearance Methadone accumulation & overdose toxicity. Respiratory depression, sedation, increased QTc. Requires proactive methadone dose reduction by 25-50%.
Antiretroviral Dynamics Boosted Protease Inhibitors (Ritonavir, Lopinavir/r), Etravirine Complex induction/inhibition; ritonavir frequently acts as a net inducer of CYP2B6/3A4 over time Variable. Monitor closely; patients may require upward dose titration despite enzyme inhibition labels.
Induction Protocols & Titration Safety Guidelines
Safe outpatient OTP induction requires conservative initial dosing and slow, stepwise titration.
Day 1 Induction Algorithm
Pre-Dose Assessment: Verify objective signs of withdrawal (COWS ≥ 8 − 10 \ge 8-10 ≥ 8 − 10 ), review medical history, confirm last opioid use, and perform baseline urine drug testing and pregnancy testing.
Starting Dose: Administer 20 to 30 mg PO as a single observed dose.
Use 20 mg (or less) if the patient has low physiological tolerance, is an older adult, or has significant hepatic impairment.
Use 30 mg for patients with verified heavy physiological tolerance.
Peak Observation (2 to 4 hours post-dose):
Evaluate the patient at T max T_{\max} T m a x .
If withdrawal symptoms are fully suppressed or patient exhibits sedation → \rightarrow → do NOT provide additional medication.
If severe objective withdrawal symptoms persist → \rightarrow → an additional 5 to 10 mg may be administered.
Maximum Day 1 Total: Under federal regulations, the total Day 1 dose must not exceed 30 to 40 mg (doses > 40 >40 > 40 mg on Day 1 are prohibited unless specifically documented by the medical director).
Subsequent Titration to Maintenance
Rate of Titration: Doses should only be adjusted by 5 to 10 mg increments every 3 to 5 days .
Rationale: Because steady-state takes 4 to 10 days to achieve, daily dose increases inevitably lead to cumulative toxicity.
Therapeutic Maintenance Range: Typically 60 to 120 mg/day .
Dosages in this range are required to achieve full mu-opioid receptor blockade, eliminate cravings, and suppress illicit opioid self-administration.
Doses < 60 <60 < 60 mg/day frequently demonstrate poor treatment retention and ongoing illicit opioid use.